skip to primary navigationskip to content

[Closes 29 April 2018] Postdoc Fellow position in Pre-Clinical Genome Editing

The CRUK Cambridge Institute performs world leading science which focuses on positively impacting cancer patients' lives. The Pre-Clinical Genome Editing team focuses on making meaningful advances to understand and treat cancer, using cutting edge technologies to create authentic models of disease for study, and gaining novel biological insight.

Learn more and apply >>> 

"As a Genome Editing Specialist, you will expand the capability of our specialised Genome Editing team, allowing us to deliver a broader spectrum User-driven projects. You will also aggressively drive the innovation and application of Genome Editing technologies in translational research. A key focus will be to establish and translate emerging or novel technologies to an in vivo setting, prototyping and working up new methodologies in vitro, and building upon our functional genomics capabilities. "

Minimum Requirements

- A PhD or equivalent

- Demonstrable evidence of driving a research project in an autonomous fashion

- Expertise in genome editing technologies is essential (preference is given to expertise in dCas9-based approaches, base editing, and non-SpCas9 CRISPR systems)

- Expertise in advanced molecular techniques (eg Cell Culture, Viral Vectors, Gibson assembly, recombineering)

- Experience of Synthetic Biology and simple model organisms is essential

- Experience with library screening and NGS highly desirable

- Statistical computation (eg R) fluency

- Experience of in vivo Genome Editing desirable (any model organism system)

- Ability to work independently and as part of a hard-working, motivated and enthusiastic team.

- Proactive and flexible, with a proven ability to perform under pressure.

- Excellent and effective communication skills are essential to this role.

Filed under:


The Synthetic Biology Strategic Research Initiative provides a hub for anyone interested in Synthetic Biology at the University of Cambridge, as well as commercial partners and external collaborators.